Skip to content

Study · Systematic review · 2026

7 results

Pharmacotherapy for Children and Adolescents With Overweight or Obesity: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.

Luo L, Huang T, Yan Z, Qi Y, Wei Q, Wang H, Liu N, Xuan Y, Chen Y, Zhao J, Xin C, Hu R, Zhang S

Diabetes, obesity & metabolism17 Jun 2026Cited by 1 (Europe PMC)

PMID42310900 (opens in a new tab)PMCIDPMC13448963 (opens in a new tab)DOI10.1111/dom.70986 (opens in a new tab)PepBankPUB-42310900
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In children and adolescents with overweight or obesity, semaglutide reduced the 95th BMI percentile versus lifestyle modification alone (MD -20.40%, 95% CI -24.22 to -16.58).

    In plain wordsIn children and adolescents with overweight or obesity, semaglutide reduced the 95th BMI percentile more than lifestyle alone.

    Peptide
    Semaglutide
    Outcome
    Decrease95th BMI percentile
    Study

    n: not reported in source

    Comparator
    Lifestyle modification alone
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference
    −20.4%
    versus lifestyle alone; 95% CI -24.22 to -16.58

    Source sentences

    Summary
    Compared with lifestyle modification alone, semaglutide produced the largest reduction in the 95th BMI percentile (MD -20.40%, 95% CI -24.22 to -16.58), with an additional 500 and 399 patients per 1000 person-years achieving ≥ 5% and ≥ 10% BMI reduction, respectively.
    5 context sentences
    Summary · context
    The escalating global prevalence of childhood and adolescent overweight and obesity constitutes a pressing public health issue.
    Summary · context
    This network meta-analysis aimed to compare the efficacy and safety of pharmacologic interventions as adjuncts to lifestyle therapy in this population.
    Summary · context
    Randomized controlled trials (RCTs) were sourced from systematic searches of PubMed, Embase (using the OVID platform), the Cochrane Library (CENTRAL), the WHO International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov from database inception to July 28, 2025.
    Summary · context
    A frequentist network meta-analysis was performed using a random-effects model.
    Summary · context
    A total of 41 RCTs (N = 3923) were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In children and adolescents with overweight or obesity, semaglutide versus lifestyle modification alone produced 500 additional patients per 1000 person-years achieving at least 5% BMI reduction.

    In plain wordsIn children and adolescents with overweight or obesity, semaglutide increased 5% BMI-reduction responders versus lifestyle alone.

    Peptide
    Semaglutide
    Outcome
    IncreaseAt least 5% BMI reduction responders
    Study

    n: not reported in source

    Comparator
    Lifestyle modification alone
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Additional patients
    500 per 1000 person-years
    versus lifestyle modification alone; at least 5% BMI reduction

    Source sentences

    Summary
    Compared with lifestyle modification alone, semaglutide produced the largest reduction in the 95th BMI percentile (MD -20.40%, 95% CI -24.22 to -16.58), with an additional 500 and 399 patients per 1000 person-years achieving ≥ 5% and ≥ 10% BMI reduction, respectively.
    5 context sentences
    Summary · context
    The escalating global prevalence of childhood and adolescent overweight and obesity constitutes a pressing public health issue.
    Summary · context
    This network meta-analysis aimed to compare the efficacy and safety of pharmacologic interventions as adjuncts to lifestyle therapy in this population.
    Summary · context
    Randomized controlled trials (RCTs) were sourced from systematic searches of PubMed, Embase (using the OVID platform), the Cochrane Library (CENTRAL), the WHO International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov from database inception to July 28, 2025.
    Summary · context
    A frequentist network meta-analysis was performed using a random-effects model.
    Summary · context
    A total of 41 RCTs (N = 3923) were included.
  3. 03HumanSystematic reviewEfficacy outcome

    In children and adolescents with overweight or obesity, semaglutide versus lifestyle modification alone produced 399 additional patients per 1000 person-years achieving at least 10% BMI reduction.

    In plain wordsIn children and adolescents with overweight or obesity, semaglutide increased 10% BMI-reduction responders versus lifestyle alone.

    Peptide
    Semaglutide
    Outcome
    IncreaseAt least 10% BMI reduction responders
    Study

    n: not reported in source

    Comparator
    Lifestyle modification alone
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Additional patients
    399 per 1000 person-years
    versus lifestyle modification alone; at least 10% BMI reduction

    Source sentences

    Summary
    Compared with lifestyle modification alone, semaglutide produced the largest reduction in the 95th BMI percentile (MD -20.40%, 95% CI -24.22 to -16.58), with an additional 500 and 399 patients per 1000 person-years achieving ≥ 5% and ≥ 10% BMI reduction, respectively.
    5 context sentences
    Summary · context
    The escalating global prevalence of childhood and adolescent overweight and obesity constitutes a pressing public health issue.
    Summary · context
    This network meta-analysis aimed to compare the efficacy and safety of pharmacologic interventions as adjuncts to lifestyle therapy in this population.
    Summary · context
    Randomized controlled trials (RCTs) were sourced from systematic searches of PubMed, Embase (using the OVID platform), the Cochrane Library (CENTRAL), the WHO International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov from database inception to July 28, 2025.
    Summary · context
    A frequentist network meta-analysis was performed using a random-effects model.
    Summary · context
    A total of 41 RCTs (N = 3923) were included.
  4. 04HumanSystematic reviewEfficacy outcome

    In children and adolescents with overweight or obesity, liraglutide reduced the 95th BMI percentile more than lifestyle modification alone.

    In plain wordsIn children and adolescents with overweight or obesity, liraglutide reduced the 95th BMI percentile more than lifestyle alone.

    Peptide
    Liraglutide
    Outcome
    Decrease95th BMI percentile
    Study

    n: not reported in source

    Comparator
    Lifestyle modification alone
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide and exenatide also significantly reduced the 95th BMI percentile compared with lifestyle modification alone, although the reductions were smaller than those achieved with semaglutide and phentermine-topiramate.
    5 context sentences
    Summary · context
    The escalating global prevalence of childhood and adolescent overweight and obesity constitutes a pressing public health issue.
    Summary · context
    This network meta-analysis aimed to compare the efficacy and safety of pharmacologic interventions as adjuncts to lifestyle therapy in this population.
    Summary · context
    Randomized controlled trials (RCTs) were sourced from systematic searches of PubMed, Embase (using the OVID platform), the Cochrane Library (CENTRAL), the WHO International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov from database inception to July 28, 2025.
    Summary · context
    A frequentist network meta-analysis was performed using a random-effects model.
    Summary · context
    A total of 41 RCTs (N = 3923) were included.
  5. 05HumanSystematic reviewEfficacy outcome

    In children and adolescents with overweight or obesity, the network meta-analysis reported smaller 95th-BMI-percentile reduction magnitude with liraglutide than semaglutide.

    In plain wordsIn children and adolescents with overweight or obesity, liraglutide had a smaller BMI-percentile reduction than semaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseMagnitude of 95th-BMI-percentile reduction versus semaglutide
    Study

    n: not reported in source

    Comparator
    semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide and exenatide also significantly reduced the 95th BMI percentile compared with lifestyle modification alone, although the reductions were smaller than those achieved with semaglutide and phentermine-topiramate.
    6 context sentences
    Summary · context
    The escalating global prevalence of childhood and adolescent overweight and obesity constitutes a pressing public health issue.
    Summary · context
    This network meta-analysis aimed to compare the efficacy and safety of pharmacologic interventions as adjuncts to lifestyle therapy in this population.
    Summary · context
    Randomized controlled trials (RCTs) were sourced from systematic searches of PubMed, Embase (using the OVID platform), the Cochrane Library (CENTRAL), the WHO International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov from database inception to July 28, 2025.
    Summary · context
    A frequentist network meta-analysis was performed using a random-effects model.
    Summary · context
    A total of 41 RCTs (N = 3923) were included.
    Summary · context
    Compared with lifestyle modification alone, semaglutide produced the largest reduction in the 95th BMI percentile (MD -20.40%, 95% CI -24.22 to -16.58), with an additional 500 and 399 patients per 1000 person-years achieving ≥ 5% and ≥ 10% BMI reduction, respectively.
  6. 06HumanSystematic reviewEfficacy outcome

    In children and adolescents with overweight or obesity, the network meta-analysis reported smaller 95th-BMI-percentile reduction magnitude with liraglutide than phentermine-topiramate.

    In plain wordsIn children and adolescents with overweight or obesity, liraglutide had a smaller BMI-percentile reduction than phentermine-topiramate.

    Peptide
    Liraglutide
    Outcome
    DecreaseMagnitude of 95th-BMI-percentile reduction versus phentermine-topiramate
    Study

    n: not reported in source

    Comparator
    phentermine-topiramate
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide and exenatide also significantly reduced the 95th BMI percentile compared with lifestyle modification alone, although the reductions were smaller than those achieved with semaglutide and phentermine-topiramate.
    6 context sentences
    Summary · context
    The escalating global prevalence of childhood and adolescent overweight and obesity constitutes a pressing public health issue.
    Summary · context
    This network meta-analysis aimed to compare the efficacy and safety of pharmacologic interventions as adjuncts to lifestyle therapy in this population.
    Summary · context
    Randomized controlled trials (RCTs) were sourced from systematic searches of PubMed, Embase (using the OVID platform), the Cochrane Library (CENTRAL), the WHO International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov from database inception to July 28, 2025.
    Summary · context
    A frequentist network meta-analysis was performed using a random-effects model.
    Summary · context
    A total of 41 RCTs (N = 3923) were included.
    Summary · context
    Compared with lifestyle modification alone, semaglutide produced the largest reduction in the 95th BMI percentile (MD -20.40%, 95% CI -24.22 to -16.58), with an additional 500 and 399 patients per 1000 person-years achieving ≥ 5% and ≥ 10% BMI reduction, respectively.
  7. 07HumanSystematic reviewEfficacy outcome

    In children and adolescents with overweight or obesity, the network meta-analysis reported greater 95th-BMI-percentile reduction magnitude with semaglutide than liraglutide.

    In plain wordsIn children and adolescents with overweight or obesity, semaglutide had a greater BMI-percentile reduction than liraglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseMagnitude of 95th-BMI-percentile reduction versus liraglutide
    Study

    n: not reported in source

    Comparator
    liraglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide and exenatide also significantly reduced the 95th BMI percentile compared with lifestyle modification alone, although the reductions were smaller than those achieved with semaglutide and phentermine-topiramate.
    6 context sentences
    Summary · context
    The escalating global prevalence of childhood and adolescent overweight and obesity constitutes a pressing public health issue.
    Summary · context
    This network meta-analysis aimed to compare the efficacy and safety of pharmacologic interventions as adjuncts to lifestyle therapy in this population.
    Summary · context
    Randomized controlled trials (RCTs) were sourced from systematic searches of PubMed, Embase (using the OVID platform), the Cochrane Library (CENTRAL), the WHO International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov from database inception to July 28, 2025.
    Summary · context
    A frequentist network meta-analysis was performed using a random-effects model.
    Summary · context
    A total of 41 RCTs (N = 3923) were included.
    Summary · context
    Compared with lifestyle modification alone, semaglutide produced the largest reduction in the 95th BMI percentile (MD -20.40%, 95% CI -24.22 to -16.58), with an additional 500 and 399 patients per 1000 person-years achieving ≥ 5% and ≥ 10% BMI reduction, respectively.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.